secondary progressive multiple sclerosis
Neurology · 2019–2024
2decisions
1medicine
1carried consumer input
3individual submissions
Every decision
| Medicine | Meeting | Outcome | Consumer input |
|---|---|---|---|
| siponimod Treatment of adult patients with secondary progressive multiple sclerosis (SPMS), specifically for intermediate and extensive metabolisers requiring a 1 mg… | Mar 2024 | Recommended with restriction | none received |
| siponimod Treatment of secondary progressive multiple sclerosis (SPMS) in adults with documented progressive disability and evidence of prior relapsing-remitting disease… | Nov 2019 | Not recommended | 3 individuals MS Australia · MS Research Australia |
Who spoke
MS Australia · MS Research Australia
Conditions are classified by a language model from the indication text of each submission, so an individual label here can be wrong. Consumer input is read from the document's own consumer comments section: 1 of 2 decisions since 2014 carried some. Silence means no comment reached the committee through that facility, not that nobody was affected. More on how this was built.